Group 1 - The core viewpoint of the article highlights that Junshi Biosciences' major shareholder has increased their stake, and the company is advancing its monkeypox vaccine and other pipelines, demonstrating a full industry chain capability [1][2]. Group 2 - Recent events include the major shareholder, Xiong Jun, increasing their stake by acquiring 100,000 A-shares, which represents 0.01% of the total share capital, with an investment of 3.8384 million yuan. The shareholder plans to invest no less than 100 million yuan over the next 12 months, indicating internal confidence [2]. - The company is actively developing innovative drugs, with its monkeypox vaccine pipeline currently in the preclinical stage. In October 2023, Junshi Biosciences collaborated with several research institutions to develop a recombinant protein vaccine for monkeypox, showcasing its full industry chain capability [2]. Group 3 - In terms of stock performance, Junshi Biosciences' A-share price fluctuated significantly over the past week, closing at 35.72 yuan on February 10, 2026, with a single-day increase of 0.90%. However, by February 12, the price fell to 34.72 yuan, reflecting a decrease of 0.88% [3]. - The trading volume on February 12 showed a net outflow of 18.32 million yuan from institutional investors, while retail investors saw a net inflow of the same amount. The financing balance remained high at 1.427 billion yuan as of February 11, indicating market divergence [3]. Group 4 - Institutional perspectives from Guojin Securities suggest that the innovative drug sector is entering a performance disclosure window, with Junshi Biosciences and similar companies expected to reduce losses or turn profitable. The report emphasizes a shift in investment strategy towards selective focus on cutting-edge areas such as ADC and bispecific antibodies, while also highlighting the importance of companies with independent production capabilities [4]. - Junshi Biosciences is recognized as a leading player in the domestic innovative drug sector, with its international expansion and pipeline progress, such as the volume increase of Tislelizumab, being long-term focal points, although research and development risks should be considered [4].

Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

2025年，沪市公司经营韧性与结构亮点进一步显现，在"质"与"量"的双重维度上，助力中国经济破浪前 行。数据显示，截至2月9日，271家沪市主板公司发布2025年业绩预告，其中168家预增、85家预计扭 亏。391家科创板公司以业绩预告或快报形式披露了2025年业绩情况，近六成公司预计净利润实现同比 增长，其中39家预计净利润同比倍增、51家预计扭亏为盈。 一幅稳增长、优结构的沪市公司全年发展图景徐徐展开。记者关注到，业绩突出的公司主要集中在有色 金属、电子等行业。有色金属受产品价格与产销量共同驱动，电子行业在AI需求带动下维持较快增 长。与此同时，一批龙头公司预计盈利规模仍处于高位，持续发挥沪市主板"压舱石"作用。 有色金属行业发展尽显韧性 2025年，在全球地缘政治摩擦多发和主要经济体降息预期的推动下，黄金的避险与货币属性愈加显现， 黄金价格屡创新高，直接增厚了拥有巨量黄金储备企业的利润。 有色行业规模以上企业工业增加值增长6.9%，高于全国规上工业增加值增速1.0个百分点，十种有色金 属产量首次突破8000万吨大关。规模以上企业实现利润总额5284.5亿元，同比增长25.6%，创下历史新 高。下游新兴产 ...

Group 1 - The core point of the news is that Junshi Biosciences (688180.SH) is currently experiencing a decline in stock price, closing at 35.03 yuan with a drop of 1.93% [1] - Junshi Biosciences was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share [1] - The stock reached its highest point at 220.40 yuan on the first day of trading but is now in a state of decline [1] Group 2 - In 2020, Junshi Biosciences raised a total of 4.836 billion yuan from its initial public offering, with a net amount of 4.497 billion yuan after deducting issuance costs [1] - The company initially planned to raise 2.7 billion yuan, which was exceeded by 1.797 billion yuan [1] - The total fundraising amount from the company's specific issuance of A-shares in 2022 was approximately 3.7765 billion yuan, with a net amount of about 3.7448 billion yuan after fees [2] - The total amount raised by Junshi Biosciences from both fundraising rounds is 8.612 billion yuan [2]

Core Viewpoint - Junshi Biosciences has established a new subsidiary in Shanghai with a registered capital of 500 million yuan, indicating its ongoing expansion and investment in biotechnology [1] Group 1 - The newly established subsidiary is named Shanghai Junyile Biotechnology Co., Ltd. [1] - The registered capital of the new company is 500 million yuan [1] - The business scope of the subsidiary includes technology services, development, consulting, exchange, transfer, promotion, import and export of goods and technology, as well as information consulting services (excluding licensed information consulting services) [1] Group 2 - Junshi Biosciences holds 100% ownership of the new subsidiary [1]

Core Viewpoint - The upcoming Chinese New Year holiday will lead to a 10-day market closure for A-shares, while Hong Kong stocks (H-shares) will continue trading, raising questions about whether H-shares can perform independently during this period. The recent adjustments in H-shares, combined with the surge in AI applications, prompt an analysis of whether the market has reached a correction point [1][3]. Market Trends - Historically, the Hang Seng Index has shown an 82% probability of rising in the three trading days before the Spring Festival, with a 40%-60% chance of increasing after the holiday. The correlation between H-shares and A-shares has strengthened, while the correlation with U.S. stocks has weakened, suggesting a potential for passive upward movement in H-shares [3]. Sector Performance - The Hang Seng Technology Index has seen significant performance metrics, with an average increase of 72.7% from Christmas to the Spring Festival. The average increase for the Hang Seng Index during the same period is 3.8% [4]. Investment Opportunities - The recent pullback in H-shares has made valuations more attractive, with expectations of a rebound. The Hang Seng Technology Index's price-to-earnings (P/E) ratio is currently at 24.5, which is below the historical average, indicating a favorable entry point for investors [7][8]. Innovation and Drug Development - Significant partnerships in the biotech sector, such as the collaboration between Innovent Biologics and Eli Lilly, highlight the potential for innovation in the pharmaceutical industry. This partnership includes a $350 million upfront payment and potential milestone payments totaling up to $8.5 billion [9]. Consumer Sector Dynamics - As the Spring Festival approaches, consumer activity is expected to rise, particularly in sectors like gold retail and hospitality. Government policies aimed at boosting consumption are likely to enhance market sentiment and drive growth in the consumer sector [11]. Dividend Strategies - In a low-interest-rate environment, dividend strategies are becoming increasingly attractive. The dividend yield for H-shares remains higher compared to A-shares, making them a compelling option for investors seeking stable returns [12][13]. Automotive Sector Growth - The automotive sector is poised for growth due to supportive policies and technological advancements in smart driving. The introduction of new policies for electric vehicle purchases is expected to stimulate demand, while advancements in autonomous driving technology present further opportunities [14][15].

Group 1 - The core point of the article is that Junshi Biosciences (688180.SH) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has cumulatively increased his holdings of the company's A-shares by 100,000 shares, representing approximately 0.01% of the total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase was conducted through the Shanghai Stock Exchange system via centralized bidding [1] - The increase plan has not yet been fully implemented, and Mr. Xiong Jun will continue to increase his holdings of the company's shares opportunistically during the implementation period of the increase plan [1]

➢ 美国零售数据疲软；中国将常态化国债 买卖操作。A股窄幅震荡。上证指数收 涨0.13%报4128.37点，录得6连阳；深证 成指涨0.02%，创业板指跌0.37%。光伏 涨幅居前。恒指冲高回落，香港恒生指 数收涨0.58%报27183.15点，恒生科技指 数涨0.62%，恒生中国企业指数涨0.81%。 AI应用股、创新药大涨。大市成交额 2340.4亿港元。外盘方面，欧洲三大股 指收盘涨跌不一，美国三大股指收盘涨 跌不一，道指涨0.1%，标普500指数跌 0.33%报6941.81点，纳指跌0.59%。美国 零售销售意外停滞，市场提高今年降息 押注，关注周三发布的非农就业报告。 中国央行称将常态化开展国债买卖操作。 资料来源：彭博 2026年2月11日星期三 | 27183.15 | 0.58 | 6.06 | | --- | --- | --- | | 9242.75 | 0.81 | 3.69 | | 5451.03 | 0.62 | -1.18 | | 118.25 | -0.39 | -4.22 | | 4128.37 | 0.13 | 4.02 | | 14210.63 | 0.02 | 5.07 ...

2026年2月11日星期三 ➢ 美国零售数据疲软；中国将常态化国债 买卖操作。A股窄幅震荡。上证指数收 涨0.13%报4128.37点，录得6连阳；深证 成指涨0.02%，创业板指跌0.37%。光伏 涨幅居前。恒指冲高回落，香港恒生指 数收涨0.58%报27183.15点，恒生科技指 数涨0.62%，恒生中国企业指数涨0.81%。 AI应用股、创新药大涨。大市成交额 2340.4亿港元。外盘方面，欧洲三大股 指收盘涨跌不一，美国三大股指收盘涨 跌不一，道指涨0.1%，标普500指数跌 0.33%报6941.81点，纳指跌0.59%。美国 零售销售意外停滞，市场提高今年降息 押注，关注周三发布的非农就业报告。 中国央行称将常态化开展国债买卖操作。 183 35 3511-15 XIN YONGAN INTERNATIONAL FINANCIAL HOLDINGS LIMITED Units 3511-15, 35/F, Cosco Tower, Grand Millennium Plaza, www.yafco.com.hk 183 Queen's Road Central, Sheung Wan, Hong ...

Core Viewpoint - The chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, through various trading methods [1] Group 1: Shareholding Plan - Xiong Jun intends to increase his holdings in both A-shares and H-shares, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share acquisition plan is still in progress, and Xiong Jun will continue to purchase shares according to the outlined plan during the implementation period [1]